Title:
ウイルス免疫療法用の医薬組成物およびその使用
Document Type and Number:
Japanese Patent JP6629195
Kind Code:
B2
Abstract:
The present invention relates to a new pharmaceutical composition for viral immunotherapy, and in particular, a pharmaceutical composition for viral immunotherapy for persistent hepatitis B infection. The present pharmaceutical composition consists of an antiviral agent, an immunomodulatory agent and a recombinant hepatitis B vaccine, and is used for treating hepatitis B, in particular chronic hepatitis B. In the present pharmaceutical composition, the antiviral agent is selected from ±-IFN, nucleoside analogues, and the like, and the immunomodulatory agent is selected from GM-CSF and the like.
Inventors:
One,bin
Wang, Schanzen
Jean, Jimin
Wang, Schanzen
Jean, Jimin
Application Number:
JP2016528301A
Publication Date:
January 15, 2020
Filing Date:
July 28, 2014
Export Citation:
Assignee:
Fudan University
International Classes:
A61K39/29; A61K38/19; A61K38/21; A61K47/60; A61P31/20; A61P37/04; A61P43/00
Foreign References:
| CN1990043A | ||||
| WO2013107355A1 |
Other References:
ZHANG, J.X. et al.,Shi Jie Hua Ren Xiao Hua Za Zhi,2009年,Vol.17, No.6,p.614-7
HAIYING, L.I. et al.,J Clin Hepatol,2006年,Vol.9, No.4,p.228-30
NCT01878565, The Treatment With HBIG+GM-CSF+HBV Vaccine for Chronic Hepatitis B Patients With HBeAg Seroconversion,ClinicalTrials.gov[online],2013年 7月24日, [retrieved on 2018.04.02], Retrieved from the Internet:
VAN THIEL, D.H. et al.,J Viral Hepat,1997年,Vol.4, Suppl.1,p.101-6
HAIYING, L.I. et al.,J Clin Hepatol,2006年,Vol.9, No.4,p.228-30
NCT01878565, The Treatment With HBIG+GM-CSF+HBV Vaccine for Chronic Hepatitis B Patients With HBeAg Seroconversion,ClinicalTrials.gov[online],2013年 7月24日, [retrieved on 2018.04.02], Retrieved from the Internet:
VAN THIEL, D.H. et al.,J Viral Hepat,1997年,Vol.4, Suppl.1,p.101-6
Attorney, Agent or Firm:
Seiji Ohno
Yuko Matsuniya
Umeda Shinsuke
Hiroshi Morita
Tsukuda Seigen
Yuko Matsuniya
Umeda Shinsuke
Hiroshi Morita
Tsukuda Seigen